Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2020 Mar 3;43(5):459–467. doi: 10.1002/clc.23352

Clinical features, complications, and outcomes of exogenous and endogenous catecholamine‐triggered Takotsubo syndrome: A systematic review and meta‐analysis of 156 published cases

Shams Y‐Hassan 1,✉, Henrik Falhammar 2,3
PMCID: PMC7244299  PMID: 32125009

Abstract

Innumerable physical stress factors including externally administered catecholamines, and pheochromocytomas and paragangliomas (PPGLs) have been reported to trigger Takotsubo syndrome (TS). A systematic search of PubMed/MEDLINE identified 156 patients with catecholamine‐induced TS up to December 2017. Data were compared within the catecholamine‐induced TS cohort, but some comparisons were also done to a previously published large all‐TS cohort (n = 1750). The mean age was 46.4 ± 16.4 years (72.3% women). The clinical presentation was dramatic with high complication rates in (68.2%, n = 103; multiple complications 34.6%, n = 54). The most common TS ballooning pattern was apical or mid‐apical (45.2%, n = 69), followed by basal pattern (28.8%, n = 45), global pattern (16.0%, n = 25), mid‐ventricular (8.3%, n = 13), focal (0.6%, n = 1), and unidentified pattern (1.9%, n = 3). There was an increase in the prevalence of apical sparing ballooning pattern compared to all‐TS population (37.7% vs 18.3%, P < .00001). Higher complication rates were observed in TS with global ballooning pattern compared to apical ballooning pattern (23/25, 92% vs 38/65, 58.5%; P = .0022). Higher complication rates were observed in patients with age < 50 years than patients >50 years (73/92, 79.3% vs 29/56, 51.8%, P = 0.0009). Recurrence occurred exclusively in patients with PPGL‐induced TS (18/107 patients, 16.8%). PPGL‐induced TS was characterized by more global ballooning's pattern (22/104, 21.2% vs 3/49, 6.1%, P = 0.02), and lower left ventricular ejection fraction (25.54 ± 11.3 vs 31.82 ± 9.93, P = 0.0072) compared to exogenous catecholamine‐induced TS. In conclusion, catecholamine‐induced TS was characterized by a dramatic clinical presentation with extensive left ventricular dysfunction, and high complication rate.

Keywords: broken heart syndrome, epinephrine, myocardial stunning, norepinephrine, paraganglioma, pheochromocytoma, Takotsubo

1. BACKGROUND

Takotsubo syndrome (TS) is an acute cardiac disease entity with a clinical presentation resembling that of an acute coronary syndrome.1, 2 The syndrome is characterized by a striking regional left ventricular wall motion abnormality (LVWMA) with a circumferential pattern extending beyond the coronary artery supply territory and resulting in a conspicuous ballooning of the left ventricle during systole.3, 4 Innumerable physical stress factors have been reported to trigger the disease.5 Among the physical stressors are external administration of epinephrine6 and norepinephrine7 and the disease conditions causing increased catecholamine elevations, sometimes massively, such as pheochromocytomas and paragangliomas (PPGLs).8, 9, 10

PPGLs are catecholamine‐secreting tumors that arise from chromaffin tissue of the sympathetic nervous system.11, 12 PPGLs presentation may be vague and the interpretation of the symptoms and signs may be difficult.13 The classic triad (hypertension, hyperhidrosis, and palpitation) and paroxysmal hypertension were the symptoms that usually lead to the suspicion of PPGLs previously.13 PPGLs are more frequent in certain groups, for example, in patients with adrenal incidentalomas with 0.6% to 4.2% being affected but is otherwise generally rare.14, 15, 16 Most PPGLs are nowadays diagnosed due to an incidentaloma, then due to catecholamine excess symptoms and finally because of screening in a previously known familial syndrome (eg, multiple endocrine neoplasia type 2, von Hippel Lindau syndrome, neurofibromatosis type 1, and mutations in succinate dehydrogenase B, C, and D)12, 13, 17, 18, 19 Cushing's syndrome due to ectopic ACTH‐production from a PPGL can occasionally occur,20, 21 and thus all adrenal tumors should have a 1 mg overnight dexamethasone suppression test to exclude cortisol excess.22, 23 Sometimes an adrenal medullary hyperplasia may be the culprit of catecholamine excess.24

The data on catecholamine‐induced TS are limited and mostly consist of case reports and case series. Thus, in this systematic review and meta‐analysis, the clinical features, complications and outcomes of 156 published cases of externally administered epinephrine‐ and norepinephrine‐, and PPGL‐induced TS are described. Furthermore, a comparison was made between the whole group and a study including all‐TS population. The externally administered catecholamine‐induced TS is also compared to the PPGL‐induced TS.

2. METHODS

All cases of epinephrine‐induced TS, norepinephrine‐induced TS, and PPGL‐induced TS from 1990, the year where the Japanese term Takotsubo was introduced, to December 2017 were critically reviewed. The cases were retrieved by systematical searches in PubMed/Medline using the search terms “Takotsubo,” “apical ballooning,” “stress cardiomyopathy,” and “broken heart syndrome,” and linking them with the terms “pheochromocytoma,” “paraganglioma,” “catecholamines,” “epinephrine,” “adrenaline,” “norepinephrine,” and “noradrenaline.” Cases with PPGL‐induced transient left ventricular dysfunction where the clinical features and course were consistent with TS were also included. Articles were initially screened by title for relevance and then by abstract, with full‐text articles of potentially relevant reports reviewed. The reference lists of the retrieved full‐text studies were scanned to identify additional relevant reports. Only case‐reports or reports on a series of cases where enough information was available on every case were included (Figure 1).

Figure 1.

Figure 1

Open in a new tab

Flow chart illustrating the procedure for article inclusion and exclusion in a systematic review of cases of pheochromocytoma and paraganglioma (PPGL)‐, epinephrine‐, and norepinephrine‐triggered takotsubo syndrome (TS)

The following information was extracted from the publications: the age and gender of the patients, the clinical presentation, the type of ECG changes and the cardiac biomarkers in all patients. The TS localization was deemed by the description in the text or the available figures in the manuscripts. The results were compared with 1750 patients from the study by Templin et al5 where all types of TS (all‐TS) were included, when comparable information was available in both studies. Furthermore, the 49 cases with externally administered epinephrine‐ or norepinephrine‐induced TS were compared with the 107 cases of PPGL‐induced TS. Quality assessment tools such as the Newcastle‐Ottawa Scale (available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) was considered inappropriate because these instruments had not been developed to study case reports or series. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines were followed.

2.1. Statistical analysis

Continuous variables are presented as means ± standard deviations and categorical data as absolute values and percentages. Fisher's exact test or Chi‐square test was used as appropriate to compare categorical data, and two‐tailed unpaired student's t test was used for continuous variables. A P < .05 was considered significant.

3. RESULTS

The systematic search identified 391 potentially relevant records, with an additional 10 records (including one case of PPGL‐induced TS from 198725 with features typical for mid‐apical TS) identified through review of the reference lists. After excluding all report not reporting on original cases, 148 articles were screened for eligibility. Further 12 non‐English case reports were then excluded since information could not be extracted. Consequently, 136 publications were included; 8 publications reported on more than one case report (from 2 to 7 cases; Figure 1). Because of the extreme similarities between two reported pheochromocytoma‐induced TS cases,26, 27 one case which was reported later was excluded.27 In total, 156 cases reports (107 cases with PPGL‐induced TS,9, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43 42 cases epinephrine‐induced TS,6, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 7 cases norepinephrine‐induced TS53, 54, 55, 56, 57, 58, 59) constitute the patient cohort for the meta‐analysis. Among the cases included were two non‐English case reports (one case in Swedish60 and one in German61) where enough information could be obtained. Ten of 156 of the cases (9 PPGLs and 1 epinephrine), were deemed to be catecholamine‐induced TS but were reported before the TS‐era, that is, cases reported before 1999 when the first reports on TS were published in English. The remaining 146 cases were reported during the TS‐era.

3.1. Clinical picture and presentation

The mean age was 46.4 ± 16.4 years (range 16‐86 years). Women constituted 72.3% of the cohort. In all the patients, either external epinephrine (n = 42) or norepinephrine (n = 7) administration or PPGLs (n = 107) was documented as the most probable physical trigger factor for TS. However, in 75 of 156 patients (48.1%) additional potential trigger factors were identified (emotional stressors in 8 cases [all PPGLs] and physical stressors in 67 cases). In most of the patients with external epinephrine‐ or norepinephrine‐induced TS, the disease conditions, which indicated catecholamine administration, could have been a potential trigger factor for TS.

The most common clinical presentation was chest pain, which occurred alone in 22.4% (n = 35) of the patients. Other presenting symptoms were syncope (6.4%, n = 10), dyspnea in (4.5%, n = 7), abdominal pain (3.8%, n = 6), and headache (3.8%, n = 6). Signs and symptoms suggestive of PPGLs (such as dizziness, palpitation, profuse sweating, pallor, headache and hypertension)13 alone were the presenting symptom in 6.4% (n = 10; exclusively PPGL patients). Signs and symptoms suggestive of PPGLs were associated with chest pain in further 19.2% (n = 30), with abdominal pain in 5.1% (n = 8), and with dyspnea in 4.5% (n = 7). Severe hemodynamic compromise was the presenting feature in 6.4% (n = 10; pulmonary edema 2.6% n = 4, circulatory failure 1.9% n = 3, and cardiogenic shock 1.9% n = 3). Arrhythmias, including ventricular tachycardia, occurred in 4.5% (n = 7), and other ECG changes were the presenting features in another 2.6% (n = 4). Other presenting symptoms were cough (1.9%, n = 3), hypoxia (1.3%, n = 2), and fever (0.6%, n = 1).

Information on electrocardiographic (ECG) changes was available in 141 patients (90.4%; Table 1). Among important ECG changes were ST‐elevation myocardial infarction (STEMI)‐like changes (35.5%, n = 50), T‐wave inversion (17.7%, n = 25), ST depression (22.7%, n = 32), peaked T waves (3.5%, n = 5), and sinus tachycardia (7%, n = 10). Non‐specific ECG changes was found in 7% (n = 10). Normal ECG was found in only 3.5% (n = 5). The most common ballooning pattern was apical or mid‐apical (45.2%, n = 69) followed by basal (inverted) pattern (28.8%, n = 45), global pattern (16.0%, n = 25), mid‐ventricular (8.3%, n = 13), focal (0.6%, n = 1), and unidentified pattern (1.9%, n = 3). The left ventricular ejection fraction (EF), which was available in 105 patients, was markedly reduced to 27.51 ± 11.23%.

Table 1.

Catecholamine‐induced takotsubo syndrome (TS) compared with all‐TS (Templin et al5), and pheochromocytoma/paraganglioma‐induced TS compared to combined epinephrine/norepinephrine drug‐induced TS

PPGL‐E/NE‐induced TS All‐TS (Templin et al,5) P valuesa PPGL‐TS Combined E/NE‐TS P valueb
(n = 156) (n = 1750) (n = 107) (n = 49)
Mean age (y) 46.37 ± 16.40 66.4 ± 13.1 <.0001 47.1 ± 15.9 44.81 ± 17.53 .42
(16–86) (16‐86) (16‐81)
(n = 153) (n = 107) (n = 49)
Gender, female (n) 112 (72.3%) 1571 (89.8%) <.00001 78 (72.9%) 34 (70.8%) .85
(n = 155) (n = 48)
Presenting symptom
chest pain (n) 65 (41.7%) 1226 (75.9%) <.00001 46 (43.0%) 19 (39.6%) .73
(n = 1619) (n = 48)
Heart rate (beats/min) 114.0 ± 29.8 87.5 ± 21.8 <.0001 117.7 ± 30.1 104.7 ± 27.4 .0759
(n = 80) (n = 57) (n = 23)
Precipitating stressors
Emotional (n) c 485 (27.7%) N/A c c
Physical (n) 156 (100%) 630 (36.0%) N/A 107 (100%) 49 (100%) NS
Both emotional and physical (n) 137 (7.8%) N/A N/A N/A
No triggers (n) 0 (0%) 498 (28.5%) N/A 0 (0%) 0 (0%) NS
ECG changes
STEMI‐like changes (n) 50 (35.5%) 690 (43.7%) .06 35 (36.5%) 15 (33.3%) .85
(n = 141) (n = 1578) (n = 96) (n = 45)
ST‐depression (n) 32 (22.7%) 131 (8.3%) <.00001 25 (26,0%) 7 (15,6%) .20
(n = 141) (n = 1578) (n = 96) (n = 45)
Myocardial infarction biomarkers (n)

126 (97.7%)

(n = 129)

 87.0% .0001

83 (96.5%)

(n = 96)

43 (100%)

(n = 45; N/A n = 6)

 .55
Ejection fraction (%)

27.5 ± 11.2

(n = 105)

 41.1% ± 11.8 <.0001

25.5 ± 11.3

(n = 72)

31.8 ± 9.9

(n = 33)

 .0072
TS localization pattern (n) (n = 153) (n = 1750) (n = 104) (n = 49)
Apical (n) 69 (45.2%) 1430 (81.7%) <.00001 47 (43.9%) 22 (44.9%) .90
Mid‐ventricular (n) 13 (8.3%) 255 (14.6%) .039 6 (5.6%) 7 (14.3%) .12
Basal (n) 45 (28.8) 39 (2.2%) <.00001 28 (26.2%) 17 (34.7%) .35
Global (n) 25 (16.0%) 0 (0%) <.00001 22 (20.6%) 3 (6.1%) .02
Focal (n) 1 (0.6%) 26 (1.5%) .72 1 (0.9%) 0 (0%) 1.0
Unidentified (n) 3 (1.9%) 3 (2.8)
Combined in‐hospital complications (n)

103 (68.2%)

(n = 151)

374(21.8%)

(1716)

 <.00001

74 (71.8%)

(n = 103)

29 (60.4%)

(n = 48)

 .19
Cardiogenic shock (n)

57 (37.7%)

(n = 151)

170 (9.9%)

(n = 1716)

 <.00001

41 (39.8%)

(n = 103)

16 (33.3%)

(n = 48)

 .48
Death (n)

6 (3.8%)

(n = 156)

72 (4.1%)

(n = 1750)

 1.0

4 (3.7%)

(n = 107)

2 (4.1%)

(n = 49)

 1.0
Inotropic medications (n)

51 (32.7%)

(n = 156)

212 (12.2%)

(n = 1735)

 <.00001

35 (33.7%)

(n = 104)

15 (30.6%)

(n = 49)

 .85
TS recurrence rate (n)

19 (12.3%)

(n = 155)

 57 (3.3%) <.00001 18 (16.8%) 1d N/A
Open in a new tab

Abbreviations: ECG, electrocardiogram; NA, not available; N/A, not applicable; PPGL‐E/NE, Pheochromocytoma and paraganglioma‐Epinephrine/Norepinephrine; STEMI, ST‐elevation myocardial infarction; TS, takotsubo syndrome.

a

P value PPGL‐E/NE‐TS vs all‐TS.

b

P value PPGL‐TS vs Combined E/NE‐TS.

c

Please see the text regarding other potential trigger factors.

d

May be recurrent or may be induced by norepinephrine.

STEMI‐like ECG changes and T‐wave inversions were significantly more prevalent in apical ballooning pattern compared to basal ballooning pattern (STEMI n = 34 and T‐wave inversions n = 19 in 69 patients with apical ballooning vs STEMI n = 3 and T‐wave inversion n = 1 in 45 patients with basal ballooning pattern, P < .00001). In contrast, ST‐depression and peaked T waves were significantly more prevalent in basal ballooning pattern compared to that of apical ballooning's pattern (ST‐depression n = 23 and peaked T‐waves n = 5 in 45 patients with basal ballooning pattern vs ST‐depression n = 4 and peaked T‐waves n = 0 in 69 patients with apical ballooning pattern, P < .00001).

The myocardial “infarction” biomarkers were in available in 129 patients (82.7%). It was increased in 97.7% (n = 126). In 121 patients (77.5%), information on coronary angiography was available. In 98.3% (n = 119), the coronary angiography was normal. Only 1.7% (n = 2) had signs of obstructive coronary artery disease.

3.2. Complications and outcomes

Information on complications was available in 151 of 156 patients (96.8%). Complications occurred in 68.2% (n = 103) (Table 1). Multiple complications were found in 34.6% (n = 54); the most common combination of complications were heart failure, pulmonary edema, cardiogenic shock, and circulatory and respiratory failure. Heart failure occurred in 53.0% (n = 80), cardiogenic shock in 37.7% (n = 57), pulmonary edema in 37.1% (n = 56), respiratory failure in 12.6% (n = 19), thrombo‐embolic complications in 9.3% (n = 14), arrhythmias including ventricular tachycardia in 8.6% (n = 13), cardiac arrest in 6.6% (n = 10), metabolic acidosis in 4.6% (n = 7), multiple organ failure in 4.0% (n = 6), electro‐mechanic dissociation in 2.6% (n = 4), and left ventricular outlet tract obstruction in 0.7% (n = 1). Significantly higher complication rates were observed in TS with global ballooning pattern compared to apical ballooning pattern (23/25, 92.0% vs 38/65, 58.5%; P = .0022). The complications occurred in 71.1% (32/45) of the basal ballooning pattern of TS compared to 58.5% (38/65) of the apical ballooning pattern (P = .227). There was no difference in the rate of complications between men and women (69.8% vs 67.3%; P = .85). In contrast, the complication rates were higher in patients aged <50 years than patients aged >50 years (73/92, 79.3% vs 29/56, 51.8%; P = .0009). Inotropic medications were used in 33.1% (50/151). The most common used inotropic medication alone or in combinations were dobutamine, norepinephrine, epinephrine, amrinone, or milrinone. Mechanical ventilation was used in 25.8% (34/132). Extracorporeal life support (ECLS), veno‐arterial extra‐corporeal membrane oxygenation (ECMO), percutaneous cardiopulmonary support, left ventricular assist device, and intra‐aortic balloon pump were used alone or in combination in 21.5% (31/144). Recurrence occurred exclusively in patients with PPGL‐induced TS (16.8%, 18/107).

In total 3.8% (n = 6) died; 7% in the male group (n = 3), and 2.7% (n = 3) in the female group (P = .35). Death occurred in 3.7% (n = 4) of the patients with PPGL‐, 4% (n = 2) with exogenous catecholamine‐induced TS. Mortality during recurrence of PPGL‐induced TS was high (11%, 2/18). Different inotropic medications alone or in combinations were used in most patients who died (67%, 4/6); this may have contributed to the deaths.

3.3. Catecholamine‐induced TS vs all‐TS population

Compared to all‐TS population,5 the patients in catecholamine‐induced TS were 20 years younger (P < .0001; Table 1). The TS prevalence in men was increased to 27.7% in catecholamine‐induced TS compared to 10.2% in all‐TS population; however, women were still predominating. The disease was more severe in catecholamine‐induced TS with significantly higher heart rate and lower left ventricular ejection fraction; 16.3% of patients had global left ventricular dysfunction compared to 0% in all‐TS population.5 There was also increase in the prevalence of apical sparing ballooning pattern compared to all‐TS population (37.7% vs 18.3%, P < .00001). The disease severity was reflected in significantly higher complication rate (68.2% vs 21.8%), more cardiogenic shock (37.7% vs 9.9%) and higher use of inotropic medications (32.7% vs 12.2%). Significantly higher recurrence rate was reported in catecholamine‐induced TS (all in patients with PPGL‐induced TS) than all‐TS population.

3.4. Exogenous catecholamine‐induced TS vs PPGL‐induced TS

The disease in PPGL‐induced TS was more severe with significantly increased prevalence of global TS‐pattern and lower left ventricular ejection fraction (Table 1). Complication rates were higher in PPGL‐induced TS, but this did not reach significant levels.

4. DISCUSSION

This systematic review and meta‐analysis reports hitherto on the largest number of patients (n = 156) with exogenous (epinephrine and norepinephrine) catecholamine‐ and endogenous (PPGLs) catecholamine‐induced TS. The main findings were that a substantial number of patients presented with severe hemodynamic compromise such as pulmonary edema, cardiogenic shock, circulatory failure, and arrhythmias. Considerable numbers of patients had global left ventricular dysfunction and marked depression of left ventricular ejection fraction. This was reflected in high complication rates during admission where two‐thirds of the patients suffered complications and one third had multiple complications. Worth mentioning is that the description of LVWMA was not always accurate especially in the cases described before the TS‐era. Five out of nine PPGL‐induced TS published before 2000 were described to have myocardial depression or severe left ventricular dysfunction with a clinical course consistent with TS.62, 63, 64, 65, 66 The other four patients had typical apical or basal (inverted) TS pattern.25, 67, 68, 69 All cases with severe left ventricular dysfunction were deemed to have global TS in this study. Global TS induced by other physical factors has also been reported.70, 71 Patients with PPGL‐induced TS may deteriorate rapidly and the TS localization may transform from regional to global.10 Such change has been well‐demonstrated in a case where the patient had mid‐basal TS during the first admission day and this progressed rapidly to severe biventricular failure during the following day.72 Several cases with PPGL‐induced TS with such startling course complicated by respiratory failure, metabolic acidosis and cardiogenic shock have been reported.73, 74 In one study constituted of 140 patients with PPGLs,75 15 patients (10.7%) suffered “acute catecholamine cardiomyopathy”. Six out of 15 patients displayed classical mid‐apical or mid‐basal (inverted) TS. The remainder had severe extensive or global hypokinesia and a clinical picture of pulmonary edema. These findings may indicate that patients with PPGL‐triggered global biventricular failure may in fact have global TS.

Higher complication rates were observed in patients aged <50 years than those >50 years. Mortality was higher in men (7%) than women (2.6%). These findings are in line with what other investigators have reported in TS in general.5

There was an increased prevalence of apical sparing ballooning pattern (37.7%; basal pattern in 28.8%, midventricular ballooning pattern in 8.3%, and focal pattern in 0.6%). In PPGL‐induced TS, high recurrence rate (16.8%) was reported. The high recurrence rate of TS in PPGL‐induced TS population was most likely attributed to the delay in the PPGL diagnosis where episodes of massive catecholamine elevation had acted as a trigger factor.76

The more severe disease in PPGL‐induced TS than in exogenous catecholamine‐induced TS may be attributed to higher catecholamine surge in the former.9 Unfortunately, it was not possible to evaluate the degree of catecholamine elevations in PPGL‐induced TS in comparison to that of externally administered catecholamines. However, it has been reported that in external epinephrine‐induced TS, the administration of >1 mg epinephrine was associated with significantly higher complication rate than administration of ≤1 mg epinephrine (92% vs 42.9%).6

4.1. Implication of the findings in catecholamine‐induced TS on the pathogenesis of TS

One hypothesis in the pathogenesis of TS is epinephrine‐induced switch in signal trafficking in the apical left ventricular myocardium causing apical ballooning.77 In the current systematic review and meta‐analysis epinephrine was involved in triggering TS in 42 patients with external epinephrine administration and most of the 107 patients with PPGL‐triggered TS. Interestingly, 37.7% of catecholamine‐induced TS had apical sparing TS pattern, which was significantly higher than 18.3% of all‐TS population.5 This finding strongly challenges epinephrine‐induced switch in signal trafficking in the apical left ventricular myocardium. The higher prevalence of apical sparing TS pattern in epinephrine‐induced TS and PPGL‐induced TS have also been reported in other studies.6, 8, 9, 78 Furthermore, almost all TS studies have, apart from PPGL‐induced TS, shown either normal or mild to moderate plasma epinephrine elevation.79 Consequently, it is justified to conclude that there is no direct causal relation between epinephrine and TS but epinephrine may, as any other physical trigger factor, induce TS through sympathetic nervous system hyper‐activation including cardiac sympathetic nerve terminals with norepinephrine seethe and spill over.1, 10, 80

4.2. Limitations

The analysis of catecholamine‐induced TS was based on retrospective studies of case reports or series with the inherent limitations of all retrospective studies, in particularly that of ascertainment bias. The absolute levels of the cardiac biomarkers and catecholamine levels could not be utilized for the estimation of comparable mean values because of lack of standardization and uniformity across the case reports. The TS localization pattern was not always accurate, and this point has been discussed previously.81 The possibility of additional trigger factors, which could have triggered TS, especially in patients with exogenous catecholamine‐induced TS, cannot be ruled out.82, 83

5. CONCLUSIONS

The clinical features, complications and outcome of the hitherto largest number of patients with exogenous and endogenous catecholamine‐induced TS are described in this systematic review and meta‐analysis. Catecholamine‐induced TS was characterized by a dramatic clinical presentation with extensive left ventricular dysfunction, and high complication rates.

CONFLICT OF INTEREST

The authors declare they have no conflict of interest.

ACKNOWLEDGMENT

This study was funded by Magnus Bergvall Foundation (Grant number 2017–02138 and 2018–02566).

Y‐Hassan S, Falhammar H. Clinical features, complications, and outcomes of exogenous and endogenous catecholamine‐triggered Takotsubo syndrome: A systematic review and meta‐analysis of 156 published cases. Clinical Cardiology. 2020;43:459–467. 10.1002/clc.23352

Funding information Magnus Bergvall Foundation, Grant/Award Numbers: 2018–02566, 2017–02138

REFERENCES

  • 1. Y‐Hassan S, Tornvall P. Epidemiology, pathogenesis, and management of takotsubo syndrome. Clin Auton Res. 2018;28(1):53‐65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. 2018;39(22):2032‐2046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Dote K, Sato H, Tateishi H, Uchida T, Ishihara M. Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases. J Cardiol. 1991;21(2):203‐214. [PubMed] [Google Scholar]
  • 4. Y‐Hassan S. Acute cardiac sympathetic disruption in the pathogenesis of the takotsubo syndrome: a systematic review of the literature to date. Cardiovasc Revasc Med. 2014;15(1):35‐42. [DOI] [PubMed] [Google Scholar]
  • 5. Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373(10):929‐938. [DOI] [PubMed] [Google Scholar]
  • 6. Y‐Hassan S. Clinical features and outcome of epinephrine‐induced takotsubo syndrome: analysis of 33 published cases. Cardiovasc Revasc Med. 2016;17(7):450‐455. [DOI] [PubMed] [Google Scholar]
  • 7. Y‐Hassan S. Serotonin norepinephrine re‐uptake inhibitor (SNRI)‐, selective norepinephrine reuptake inhibitor (S‐NRI)‐, and exogenously administered norepinephrine‐induced takotsubo syndrome: analysis of published cases. Int J Cardiol. 2017;231:228‐233. [DOI] [PubMed] [Google Scholar]
  • 8. Agarwal V, Kant G, Hans N, Messerli FH. Takotsubo‐like cardiomyopathy in pheochromocytoma. Int J Cardiol. 2011;153(3):241‐248. [DOI] [PubMed] [Google Scholar]
  • 9. Y‐Hassan S. Clinical features and outcome of Pheochromocytoma‐induced Takotsubo syndrome: analysis of 80 published cases. Am J Cardiol. 2016;117(11):1836‐1844. [DOI] [PubMed] [Google Scholar]
  • 10. Y‐Hassan S, Falhammar H. Pheochromocytoma‐ and paraganglioma‐triggered Takotsubo syndrome. Endocrine. 2019;65(3):483‐493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915‐1942. [DOI] [PubMed] [Google Scholar]
  • 12. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552‐565. [DOI] [PubMed] [Google Scholar]
  • 13. Falhammar H, Kjellman M, Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr Connect. 2018;7(1):186‐192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Yeomans H, Calissendorff J, Volpe C, Falhammar H, Mannheimer B. Limited value of long‐term biochemical follow‐up in patients with adrenal incidentalomas‐a retrospective cohort study. BMC Endocr Disord. 2015;15:6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Patrova J, Jarocka I, Wahrenberg H, Falhammar H. Clinical outcomes in adrenal Incidentaloma: experience from one center. Endocrine Practice. 2015;21(8):870‐877. [DOI] [PubMed] [Google Scholar]
  • 16. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. J Clin Endocrinol Metab. 2000;85(2):637‐644. [DOI] [PubMed] [Google Scholar]
  • 17. Amar L, Servais A, Gimenez‐Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90(4):2110‐2116. [DOI] [PubMed] [Google Scholar]
  • 18. Gruber LM, Hartman RP, Thompson GB, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab. 2019;104(5):1386‐1393. [DOI] [PubMed] [Google Scholar]
  • 19. Falhammar H, Kjellman M, Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center. Endocrine. 2018;62(3):566‐575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Falhammar H, Calissendorff J, Hoybye C. Frequency of Cushing's syndrome due to ACTH‐secreting adrenal medullary lesions: a retrospective study over 10 years from a single center. Endocrine. 2017;55(1):296‐302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Gabi JN, Milhem MM, Tovar YE, Karem ES, Gabi AY, Khthir RA. Severe Cushing syndrome due to an ACTH‐producing Pheochromocytoma: a case presentation and review of the literature. J Endocr Soc. 2018;2(7):621‐630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1‐G34. [DOI] [PubMed] [Google Scholar]
  • 23. Patrova J, Kjellman M, Wahrenberg H, Falhammar H. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13‐year retrospective study from one center. Endocrine. 2017;58(2):267‐275. [DOI] [PubMed] [Google Scholar]
  • 24. Falhammar H, Stenman A, Calissendorff J, Juhlin CC. Presentation, treatment, histology, and outcomes in adrenal medullary hyperplasia compared with Pheochromocytoma. J Endocr Soc. 2019;3(8):1518‐1530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Shaw TR, Rafferty P, Tait GW. Transient shock and myocardial impairment caused by phaeochromocytoma crisis. Br Heart J. 1987;57(2):194‐198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Kim EM, Park JH, Park YS, et al. Catecholamines may play an important role in the pathogenesis of transient mid‐ and basal ventricular ballooning syndrome. J Korean Med Sci. 2008;23(5):898‐902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Park JH, Kim KS, Sul JY, et al. Prevalence and patterns of left ventricular dysfunction in patients with pheochromocytoma. J Cardiovasc Ultrasound. 2011;19(2):76‐82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Humbert O, Stamboul K, Gudjoncik A, et al. Dual diagnostic role of 123I‐MIBG Scintigraphy in inverted‐Takotsubo pattern cardiomyopathy. Clin Nucl Med. 2015;40(10):816‐818. [DOI] [PubMed] [Google Scholar]
  • 29. Sakamoto K, Kojima S, Hokimoto S, Ogawa H. Pheochromocytoma multisystem crisis with transient stress cardiomyopathy due to ruptured pheochromocytoma. BMJ Case Rep. 2015;2015:bcr2015212456. 10.1136/bcr-2015-212456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Hekimian G, Kharcha F, Brechot N, et al. Extracorporeal membrane oxygenation for pheochromocytoma‐induced cardiogenic shock. Ann Intensive Care. 2016;6(1):117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Schouver ED, Chiche O, Saady R, et al. Ischaemic colitis associated with adrenergic acute cardiomyopathy: a discovery mode of pheochromocytoma. Heart Lung Circ. 2016;25(7):e85‐e86. [DOI] [PubMed] [Google Scholar]
  • 32. Hernandez Ramirez JM, Cardenes Leon A, Gobind SR. Inverted Tako‐tsubo induced by Pheochromocytoma. Rev Esp Cardiol (Engl Ed). 2016;69(11):1107‐1109. [DOI] [PubMed] [Google Scholar]
  • 33. Petersen MH, Christophersen TB, Hansen PS, Hangaard J. Phaeochromocytoma and transient left ventricular apical ballooning syndrome. Int J Cardiol. 2016;222:479‐480. [DOI] [PubMed] [Google Scholar]
  • 34. Nepal S, Giri S, Bhusal M, Siwakoti K, Pathak R. An uncommon cause of acute pulmonary edema. JAAPA. 2016;29(9):1‐4. [DOI] [PubMed] [Google Scholar]
  • 35. Chiang YL, Chen PC, Lee CC, Chua SK. Adrenal pheochromocytoma presenting with Takotsubo‐pattern cardiomyopathy and acute heart failure: a case report and literature review. Medicine (Baltimore). 2016;95(36):e4846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. van Zwet CJ, Rist A, Haeussler A, Graves K, Zollinger A, Blumenthal S. Extracorporeal membrane oxygenation for treatment of acute inverted Takotsubo‐like cardiomyopathy from hemorrhagic Pheochromocytoma in late pregnancy. A A Case Rep. 2016;7(9):196‐199. [DOI] [PubMed] [Google Scholar]
  • 37. Gravina M, Casavecchia G, D'Alonzo N, et al. Pheochromocytoma mimicking Takotsubo cardiomyopathy and hypertrophic cardiomyopathy: A cardiac magnetic resonance study. Am J Emerg Med. 2017;35(2):353‐355. [DOI] [PubMed] [Google Scholar]
  • 38. Schmidt KH, Herholz T, Rodeck J, Abegunewardene N, Kreitner KF, Munzel T. Pheochromocytoma triggers takotsubo syndrome complicated by cerebral and peripheral embolic events. Eur Heart J. 2017;38(19):1522‐1523. [DOI] [PubMed] [Google Scholar]
  • 39. Iwase J, Yamanaka M. Sudden onset of pheochromocytoma multisystem crisis at 38 weeks of gestation resulted in intrauterine fetal death: a case report. J Obstet Gynaecol Res. 2017;43(10):1644‐1648. [DOI] [PubMed] [Google Scholar]
  • 40. Contadini D, Malagoli A, Binno SM, Villani GQ. A pheochromocytoma‐induced Takotsubo syndrome: the importance of multimodality imaging approach. Eur Heart J Cardiovasc Imaging. 2017;18(7):820. [DOI] [PubMed] [Google Scholar]
  • 41. Gagnon N, Mansour S, Bitton Y, Bourdeau I. Takotsubo‐like cardiomyopathy in a large cohort of patients with Pheochromocytoma and Paraganglioma. Endocr Pract. 2017;23(10):1178‐1192. [DOI] [PubMed] [Google Scholar]
  • 42. Lassnig E, Hafez A, Tuppy H, Weber T. Catecholamine crisis presenting as takotsubo cardiomyopathy caused by a 30‐year old ‘Benign’ thoracic tumour. Eur Heart J. 2017;38(47):3538. [DOI] [PubMed] [Google Scholar]
  • 43. Casey RT, Challis BG, Pitfield D, et al. Management of an acute catecholamine‐induced cardiomyopathy and circulatory collapse: a multidisciplinary approach. Endocrinol Diabetes Metab Case Rep. 2017;2017:17‐122. 10.1530/EDM-17-0122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Ghanim D, Adler Z, Qarawani D, Kusniec F, Amir O, Carasso S. Takotsubo cardiomyopathy caused by epinephrine‐treated bee sting anaphylaxis: a case report. J Med Case Reports. 2015;9:247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Bonnemeier H, Ortak J, Burgdorf C, et al. "the artichoke heart": the inverse counterpart of left ventricular apical ballooning. Resuscitation. 2007;72(3):342‐343. [DOI] [PubMed] [Google Scholar]
  • 46. Gicquel‐Schlemmer B, Beller JP, McHalwat A, Gicquel P. Fatal Takotsubo cardiomyopathy due to epinephrine in shoulder arthroscopy. Orthop Traumatol Surg Res. 2015;101(8):981‐982. [DOI] [PubMed] [Google Scholar]
  • 47. Jeremy B, Raphaelle F, Francois K, Pierre M, Marc G. Stress cardiomyopathy managed with extracorporeal support after self‐injection of epinephrine. Case Rep Crit Care. 2017;2017:3731069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Nazir S, Melnick S, Lohani S, Lloyd B. Rare case of stress cardiomyopathy due to intramuscular epinephrine administration. BMJ Case Rep. 2016;2016:pii: bcr2016215691. https://doi.org.10.1136/bcr-2016-215691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Belliveau D, De S. Reverse Takotsubo cardiomyopathy following exogenous epinephrine Administration in the Early Postpartum Period. Echocardiography. 2016;33(7):1089‐1091. [DOI] [PubMed] [Google Scholar]
  • 50. Keshtkar F, Dale OT, Bennett WO, Hall CE. Management of airway obstruction with nebulised adrenaline resulting in takotsubo cardiomyopathy: case report. J Laryngol Otol. 2016;130(9):883‐886. [DOI] [PubMed] [Google Scholar]
  • 51. Nassif J, Nahouli H, Khalil A, Mikhael E, Gharzeddine W, Ghaziri G. Epinephrine‐induced Takotsubo cardiomyopathy during laparoscopic myomectomy: case report and review of the literature. J Minim Invasive Gynecol. 2017;24(6):1037‐1039. [DOI] [PubMed] [Google Scholar]
  • 52. Elikowski W, Malek‐Elikowska M, Karon J, Mrozinska M, Baszko A, Horbacka K. Takotsubo cardiomyopathy after intravenous epinephrine administration following cardiac arrest provoked by pneumoperitoneum ‐ a case report. Pol Merkur Lekarski. 2017;42(250):165‐169. [PubMed] [Google Scholar]
  • 53. Lainez B, Urena M, Alvarez V, Lezaun R. Iatrogenic tako‐tsubo cardiomyopathy secondary to catecholamine administration. Rev Esp Cardiol. 2009;62(12):1498‐1499. [PubMed] [Google Scholar]
  • 54. Subramaniam A, Cooke JC, Ernest D. "inverted" tako‐tsubo cardiomyopathy due to exogenous catecholamines. Crit Care Resusc. 2010;12(2):104‐108. [PubMed] [Google Scholar]
  • 55. Redfors B, Shao Y, Omerovic E. Fatal stress‐induced cardiomyopathy in a young patient treated with adrenomimetics. Clin Res Cardiol. 2012;101(11):939‐940. [DOI] [PubMed] [Google Scholar]
  • 56. Quick S, Quick C, Schneider R, et al. Guillain‐Barre syndrome and catecholamine therapy. A potential risk for developing takotsubo cardiomyopathy? Int J Cardiol. 2013;165(3):e43‐e44. [DOI] [PubMed] [Google Scholar]
  • 57. Sherif K, Sehli S, Jenkins LA. Takotsubo cardiomyopathy after administration of norepinephrine. Proc (Bayl Univ Med Cent). 2016;29(2):166‐167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Vailas MG, Vernadakis S, Kakavia K, et al. A heartbreaking renal transplantation: is norepinephrine the culprit to blame? Transplant Proc. 2016;48(9):3088‐3091. [DOI] [PubMed] [Google Scholar]
  • 59. Ouerghi K, Boukhris M, Grall S, Desprets L, Quercy M. Reverse iatrogenic Takotsubo syndrome after accidental bolus of norepinephrine in the setting of sepsis. Kardiol pol. 2016;74(8):799. [DOI] [PubMed] [Google Scholar]
  • 60. Kashioulis P, Wangberg B, Petursson P, Ragnarsson O. Pheochromocytoma is a life threatening cause of acute heart failure. It should be considered in the differential diagnosis of unclear cases. Lakartidningen. 2013;110(38):1665‐1667. [PubMed] [Google Scholar]
  • 61. Assefa D, Welsch J, Laubner K, Burgdorf C, Kotzerke M. Cardiogenic shock due to atypical Tako‐Tsubo cardiomyopathy in a young woman with pheochromocytoma. Dtsch Med Wochenschr. 2015;140(6):422‐425. [DOI] [PubMed] [Google Scholar]
  • 62. Salathe M, Weiss P, Ritz R. Rapid reversal of heart failure in a patient with phaeochromocytoma and catecholamine‐induced cardiomyopathy who was treated with captopril. Br Heart J. 1992;68(5):527‐528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Quezado ZN, Keiser HR, Parker MM. Reversible myocardial depression after massive catecholamine release from a pheochromocytoma. Crit Care Med. 1992;20(4):549‐551. [DOI] [PubMed] [Google Scholar]
  • 64. Suga K, Tsukamoto K, Nishigauchi K, et al. Iodine‐123‐MIBG imaging in pheochromocytoma with cardiomyopathy and pulmonary edema. J Nucl Med. 1996;37(8):1361‐1364. [PubMed] [Google Scholar]
  • 65. Gatzoulis KA, Tolis G, Theopistou A, Gialafos JH, Toutouzas PK. Cardiomyopathy due to a pheochromocytoma. A reversible entity. Acta Cardiol. 1998;53(4):227‐229. [PubMed] [Google Scholar]
  • 66. Brilakis ES, Young WF Jr, Wilson JW, Thompson GB, Munger TM. Reversible catecholamine‐induced cardiomyopathy in a heart transplant candidate without persistent or paroxysmal hypertension. J Heart Lung Transplant. 1999;18(4):376‐380. [DOI] [PubMed] [Google Scholar]
  • 67. Murai K, Hirota K, Niskikimi T, et al. Pheochromocytoma with electrocardiographic change mimicking angina pectoris, and cyclic change in direct arterial pressure—a case report. Angiology. 1991;42(2):157‐161. [DOI] [PubMed] [Google Scholar]
  • 68. Elian D, Harpaz D, Sucher E, Kaplinsky E, Motro M, Vered Z. Reversible catecholamine‐induced cardiomyopathy presenting as acute pulmonary edema in a patient with pheochromocytoma. Cardiology. 1993;83(1–2):118‐120. [DOI] [PubMed] [Google Scholar]
  • 69. Nanda AS, Feldman A, Liang CS. Acute reversal of pheochromocytoma‐induced catecholamine cardiomyopathy. Clin Cardiol. 1995;18(7):421‐423. [DOI] [PubMed] [Google Scholar]
  • 70. Win CM, Pathak A, Guglin M. Not takotsubo: a different form of stress‐induced cardiomyopathy—a case series. Congest Heart Fail. 2011;17(1):38‐41. [DOI] [PubMed] [Google Scholar]
  • 71. Y‐Hassan S, Tornvall P, Tornerud M, Henareh L. Capecitabine caused cardiogenic shock through induction of global Takotsubo syndrome. Cardiovasc Revasc Med. 2013;14(1):57‐61. [DOI] [PubMed] [Google Scholar]
  • 72. Flam B, Broome M, Frenckner B, Branstrom R, Bell M. Pheochromocytoma‐induced inverted Takotsubo‐like cardiomyopathy leading to cardiogenic shock successfully treated with extracorporeal membrane oxygenation. J Intensive Care Med. 2015;30(6):365‐372. [DOI] [PubMed] [Google Scholar]
  • 73. Di Palma G, Daniele GP, Antonini‐Canterin F, Piazza R, Nicolosi GL. Cardiogenic shock with basal transient left ventricular ballooning (Takotsubo‐like cardiomyopathy) as first presentation of pheochromocytoma. J Cardiovasc Med (Hagerstown). 2010;11(7):507‐510. [DOI] [PubMed] [Google Scholar]
  • 74. Kaese S, Schulke C, Fischer D, Lebiedz P. Pheochromocytoma‐induced takotsubo‐like cardiomyopathy and global heart failure with need for extracorporal life support. Intensive Care Med. 2013;39(8):1473‐1474. [DOI] [PubMed] [Google Scholar]
  • 75. Giavarini A, Chedid A, Bobrie G, Plouin PF, Hagege A, Amar L. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart. 2013;99(19):1438‐1444. [DOI] [PubMed] [Google Scholar]
  • 76. Y‐Hassan S. Recurrent takotsubo syndrome triggered by undiagnosed pheochromocytoma. Int J Cardiol. 2015;187:369‐371. [DOI] [PubMed] [Google Scholar]
  • 77. Lyon AR, Rees PS, Prasad S, Poole‐Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy–a novel pathophysiological hypothesis to explain catecholamine‐induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med. 2008;5(1):22‐29. [DOI] [PubMed] [Google Scholar]
  • 78. Nazir S, Lohani S, Tachamo N, Ghimire S, Poudel DR, Donato A. Takotsubo cardiomyopathy associated with epinephrine use: a systematic review and meta‐analysis. Int J Cardiol. 2017;229:67‐70. [DOI] [PubMed] [Google Scholar]
  • 79. Y‐Hassan S. Plasma epinephrine levels and its causal link to takotsubo syndrome revisited: critical review with a diverse conclusion. Cardiovasc Revasc Med. 2019;20(10):907‐914. [DOI] [PubMed] [Google Scholar]
  • 80. Y‐Hassan S, De Palma R. Contemporary review on the pathogenesis of takotsubo syndrome: the heart shedding tears: norepinephrine churn and foam at the cardiac sympathetic nerve terminals. Int J Cardiol. 2017;228:528‐536. [DOI] [PubMed] [Google Scholar]
  • 81. Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako‐tsubo) cardiomyopathy. J Am Coll Cardiol. 2010;55(4):333‐341. [DOI] [PubMed] [Google Scholar]
  • 82. Tanriver Y, Betz MJ, Nibbe L, Pfluger T, Beuschlein F, Strowski MZ. Sepsis and cardiomyopathy as rare clinical manifestations of pheochromocytoma—two case report studies. Exp Clin Endocrinol Diabetes. 2010;118(10):747‐753. [DOI] [PubMed] [Google Scholar]
  • 83. Y‐Hassan S, Settergren M, Henareh L. Sepsis‐induced myocardial depression and takotsubo syndrome. Acute Card Care. 2014;16(3):1‐8. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES